Roivant Sciences(ROIV.US) Officer Sells US$4.97 Million in Common Stock

$Roivant Sciences(ROIV.US)$ Officer Sukhatme Mayukh sold 412.58K shares of common stock on Dec 18, 2024 at an average price of $12.05 for a total value of $4.97 million.Source: Announcement What is

Futu NewsDec 21 10:06

Five Reasons Why UBS Is Overweight the UK

Seeking AlphaDec 21 02:30

Roivant Sciences (ROIV) Receives a Buy From Leerink Partners

TipRanksDec 18 13:36 · Ratings

Optimistic Outlook on Roivant Sciences Despite Namilumab Setback

TipRanksDec 6 13:58

European Stocks Will See Downtrend Mid-year 2025 Before Recovery

Seeking AlphaDec 4 00:49

Roivant will cease the development of a lung disease drug due to the mid-term trial not meeting its goals.

Globe Union, December 3 | Roivant will cease the development of a drug for treating a rare lung disease because it did not demonstrate therapeutic effects on patients in a mid-stage trial. Kinevant Sciences, a subsidiary of the company, announced on Tuesday that its once-monthly injectable drug nanobody failed to meet primary and secondary endpoints in a study that evaluated 107 patients with chronic active pulmonary sarcoidosis over approximately six months. This disease causes inflammatory cell masses to form in the lungs and other organs, leading to tissue damage and organ dysfunction. According to the usa Lung Association (

Gelonghui FinanceDec 3 21:42